semuloparin sodium semuloparin sodium semuloparin (inn, usan) is an experimental antithrombotic being developed by sanofi-aventis and belongs to the group of low molecular weight heparins (lmwh). it has completed phase iii clinical trials for the prevention of thromboembolism following various kinds of surgery such as hip replacement, as well as for patients undergoing chemotherapy. semuloparin sodiumclinical dataother namesave-5026atc codenonelegal statuslegal status investigational identifierscas number9041-08-1chemspidernoneuniiv5t10n50rdecha infocard100.110.590 chemical and physical datamolar mass2000–3000 g/mol (average) like bemiparin, semuloparin is classified as an ultra-lmwh because of its low molecular mass of 2000–3000 g/mol on average. (enoxaparin has 4500 g/mol) these heparins have lower anti-thrombin activity than classical lmwhs and act mainly on factor xa, reducing the risk of bleeding.